The use of recombinant activated factor VII in the circumcision operation in the case of a congenital factor VII deficiency.
Congenital factor VII deficiency is a rare autosomal recessive hemorrhagic disorder and surgery is normally the cause of excessive bleeding. In this report, we describe the first case with congenital factor VII deficiency admitted to our clinics for the sunnet operation (circumcision), in which recombinant activated factor VII (rFVIIa; NovoSeven) was used to manage the bleeding. The patient was an 8-year old boy with moderate factor VII deficiency (factor VII level, 4%), and rFVIIa was administered at a dose of 20 microg/kg per dose during the circumcision operation. The same dose was repeated at 2, 4, 6, 9, 12, 15, 18, 21 and 24 h post operation. The circumcision operation could therefore be safely performed in patients with congenital factor VII using rFVIIa.
Canatan
Duran
D
Department of Pediatrics, Suleyman Demirel University, Isparta 32040, Turkey. dcanatan@superonline.com
Eren
Erdal
E
Ozgüner
I Faruk
IF
Duman
Handan
H
Eren
Cağatay
C
Büyükyavuz
Ilker
I
Savaş
Cağri
C
D016063:Blood Loss, Surgical / Q000517:prevention & control*; D002648:Child; D002944:Circumcision, Male / Q000009:adverse effects*; D000075202:Contraindications; D005168:Factor VII Deficiency / Q000188:drug therapy*; D015942:Factor VIIa / Q000627:therapeutic use*; D006801:Humans; D019934:International Normalized Ratio; D008297:Male; D011994:Recombinant Proteins / Q000627:therapeutic use*
D011994:Recombinant Proteins; D015942:Factor VIIa